In vitro activity of MCB3681 against Clostridium difficile strains

Rashid, Mamun Ur; Dalhoff, Axel; Weintraub, Andrej; Nord, Carl Erik

doi:10.1016/j.anaerobe.2014.07.001

Cited by 34 publications

(26 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cadazolid is currently undergoing a phase III CDI study. MCB3681 has demonstrated intro activity against C. difficile although no clinical trials are currently available . Ramoplanin is a glycolipodepsipeptide that targets bacterial cell walls like vancomycin, although at a distinct site, displays potent antimicrobial activity against C. difficile in animal CDI models .…”

Section: New Agents On the Horizon?mentioning

confidence: 99%

Australasian Society of Infectious Diseases updated guidelines for the management of Clostridium difficile infection in adults and children in Australia and New Zealand

Trubiano

Cheng

Korman

et al. 2016

Internal Medicine Journal

100

128

View full text Add to dashboard Cite

The incidence of Clostridium difficile infection (CDI) continues to rise, whilst treatment remains problematic due to recurrent, refractory and potentially severe nature of disease. The treatment of C. difficile is a challenge for community and hospital-based clinicians. With the advent of an expanding therapeutic arsenal against C. difficile since the last published Australasian guidelines, an update on CDI treatment recommendations for Australasian clinicians was required. On behalf of the Australasian Society of Infectious Diseases, we present the updated guidelines for the management of CDI in adults and children.

show abstract

Section: New Agents On the Horizon?mentioning

confidence: 99%

Australasian Society of Infectious Diseases updated guidelines for the management of Clostridium difficile infection in adults and children in Australia and New Zealand

Trubiano

Cheng

Korman

et al. 2016

Internal Medicine Journal

100

128

View full text Add to dashboard Cite

show abstract

“…It is being studied for the treatment of C. difficile -associated diarrhea (CDAD), and has progressed to phase 3 clinical trials in Europe and in the U.S. in comparison with vancomycin. 137, 138 It has very limited oral bioavailability due to its acidic and lipophilic nature, which means its activity is primarily localized to the gut. 139, 140 The drug has received QIDP and Fast Track development status from the U.S. FDA.…”

Section: Discussionmentioning

confidence: 99%

Recent advances in the rational design and optimization of antibacterial agents

et al. 2016

View full text Add to dashboard Cite

This review discusses next-generation antibacterial agents developed using rational, or targeted, drug design strategies. The focus of this review is on small-molecule compounds that have been designed to bypass developing bacterial resistance, improve the antibacterial spectrum of activity, and/or to optimize other properties, including physicochemical and pharmacokinetic properties. Agents are discussed that affect known antibacterial targets, such as the bacterial ribosome, nucleic acid binding proteins, and proteins involved in cell-wall biosynthesis; as well as some affecting novel bacterial targets which do not have currently marketed agents. The discussion of the agents focuses on the rational design strategies employed and the synthetic medicinal chemistry and structure-based design techniques utilized by the scientists involved in the discoveries, including such methods as ligand- and structure-based strategies, structure-activity relationship (SAR) expansion strategies, and novel synthetic organic chemistry methods. As such, the discussion is limited to small-molecule therapeutics that have confirmed macromolecular targets and encompasses only a fraction of all antibacterial agents recently approved or in late-stage clinical trials. The antibacterial agents selected have been recently approved for use on the U.S. or European markets or have shown promising results in phase 2 or phase 3 U.S. clinical trials.

show abstract

“…Fidaxomicin MICs against 114 C. difficile isolates were reported to be between 0.008-0.125 mg/ml in a recent study by Rashid et al 37 Fidaxomicin was shown to inhibit C. difficile toxin gene expression and consequent toxin production by measuring total mRNA and protein in another study. 38 .…”

Section: Fidaxomicinmentioning

confidence: 96%